Orthofix (OFIX) director awarded 14,965 deferred stock units as equity grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Orthofix Medical Inc. director Charles R. Kummeth reported receiving an award of 14,965 deferred stock units of common stock as a compensation grant. The units were granted at $0.00 per share, indicating they are not an open-market purchase but an equity award.
The deferred stock units vest in full on the first anniversary of the grant date, subject to his continued service. Each vested unit represents the right to receive one share of Orthofix common stock, which will be delivered within 45 days after his termination of service. Following this award, Kummeth holds 76,305 shares in total, including 42,343 previously reported deferred stock units and 2,103 shares acquired under Orthofix’s Stock Purchase Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kummeth Charles R.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 14,965 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 76,305 shares (Direct, null)
Footnotes (1)
- Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. Includes 42,343 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).
Key Figures
Deferred stock units granted: 14,965 units
Grant price per unit: $0.00 per share
Total shares after transaction: 76,305 shares
+4 more
7 metrics
Deferred stock units granted
14,965 units
Equity award to director on 2026-06-10
Grant price per unit
$0.00 per share
Compensation-related award, not market purchase
Total shares after transaction
76,305 shares
Holdings following Form 4 transaction
Previously reported deferred stock units
42,343 units
Included in post-transaction total holdings
Shares from Stock Purchase Plan
2,103 shares
Acquired under Orthofix’s SPP on 10/31/2025 and 4/30/2026
Vesting schedule
1 year from grant date
Deferred stock units vest on first anniversary
Settlement timing
Within 45 days
Settlement into stock after termination of service
Key Terms
deferred stock units, Stock Purchase Plan, Rule 16b-3(b)(5), Section 16(b)
4 terms
deferred stock units financial
"Represents an award of deferred stock units that vest in full on the first anniversary..."
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Stock Purchase Plan financial
"Includes 42,343 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan..."
A stock purchase plan is a company-run program that lets employees or qualifying investors buy the company’s shares regularly, often through paycheck deductions and sometimes at a discounted price or with matching contributions. It matters because it encourages ownership—like a workplace discount for buying company products—aligning interests between holders and managers, while affecting share supply and potential value for outside investors.
Rule 16b-3(b)(5) regulatory
"Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5)..."
Section 16(b) regulatory
"share acquisitions under the plan are exempt from Section 16(b)."
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
FAQ
What did Orthofix Medical (OFIX) director Charles R. Kummeth report in this Form 4?
Charles R. Kummeth reported receiving an equity award of 14,965 deferred stock units of Orthofix Medical common stock. This is a compensation-related grant rather than an open-market share purchase or sale.
How many Orthofix (OFIX) deferred stock units were granted to Charles R. Kummeth?
He was granted 14,965 deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Orthofix common stock, subject to vesting and later settlement terms described in the award.
When do Charles R. Kummeth’s new Orthofix (OFIX) deferred stock units vest and settle?
The 14,965 deferred stock units vest in full on the first anniversary of the grant date, if he continues serving. Vested units will convert into common stock within 45 days after his termination of service with Orthofix.
Is Charles R. Kummeth’s Orthofix (OFIX) Form 4 transaction a market purchase or sale?
No. The Form 4 describes a grant of 14,965 deferred stock units at a price of $0.00 per share. This indicates a compensation-related award, not an open-market buy or sell transaction in Orthofix shares.